Monosan (Isosorbide Mononitrate)

After oral administration, isosorbide mononitrate is converted to nitric oxide. The nitric oxide activates guanylate cyclase, raising cyclic GMP levels in vascular smooth muscle. This cascade relaxes the vessels, lowering preload and afterload, which eases chest pain and supports heart function.

The dosage of Monosan is individualized by the prescribing clinician based on the patient’s condition, response, and tolerability. Only a qualified healthcare professional should determine the appropriate dose and schedule.

Safety data for isosorbide mononitrate in pregnancy and lactation are limited. It should be used only if the potential benefit justifies any potential risk to the fetus or infant, and the decision must be made by a healthcare provider.

To request Monosan, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Monosan belongs to the organic nitrate class, offering rapid vasodilation similar to nitroglycerin but with a longer duration of action. Compared with beta‑blockers or calcium‑channel blockers, nitrates primarily reduce preload, making them useful for patients who need additional symptom control or cannot tolerate other classes.

Monosan should be stored at room temperature, below 25 °C, in its original packaging. Keep it away from moisture, heat and direct sunlight to maintain stability and potency.

Monosan is taken orally, usually with a glass of water. It can be taken with or without food, but patients should follow the specific instructions provided by their prescriber to ensure consistent absorption.

The most serious risks include severe hypotension, which can lead to fainting or syncope, and rare allergic reactions that may cause swelling, rash or breathing difficulties. Patients should seek immediate medical attention if they experience these symptoms.

Monosan should be avoided in patients with known hypersensitivity to isosorbide mononitrate or other organic nitrates, those taking phosphodiesterase‑5 inhibitors, and individuals with severe hypotension or uncontrolled low blood pressure unless directed by a physician.